LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

Search

VIRIDIAN THERAPEUTICS INC

Gesloten

SectorGezondheidszorg

24.3 7.52

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

22.16

Max

24.78

Belangrijke statistieken

By Trading Economics

Inkomsten

-14M

-101M

Verkoop

3K

75K

Winstmarge

-134,313.333

Werknemers

143

EBITDA

-14M

-100M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+68.87% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

779M

2.2B

Vorige openingsprijs

16.78

Vorige sluitingsprijs

24.3

Nieuwssentiment

By Acuity

50%

50%

165 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

VIRIDIAN THERAPEUTICS INC Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 nov 2025, 23:51 UTC

Winsten

CoreCivic Cuts Fiscal Year Guidance Amid Efforts to Launch New Detention Facilities

5 nov 2025, 23:10 UTC

Winsten

DBS Third Quarter Net Dips 2.0%

5 nov 2025, 22:55 UTC

Winsten

Arm Holdings 2Q Profit Climbs on Record Demand

5 nov 2025, 22:23 UTC

Winsten

NAB's Annual Profit Falls 2.9% Amid Higher Costs, Credit Impairments -- Update

5 nov 2025, 23:52 UTC

Winsten

United Overseas Bank 3Q Net Interest Income S$2.265B Vs. $2.46B >U11.SG

5 nov 2025, 23:49 UTC

Winsten

United Overseas Bank 3Q Total Income S$3.40B Vs. S$3.83B >U11.SG

5 nov 2025, 23:49 UTC

Winsten

United Overseas Bank 3Q Net S$443M Vs. Net S$1.61B >U11.SG

5 nov 2025, 23:45 UTC

Marktinformatie

Nikkei May Rise on Weaker Yen, U.S. Tech Rebound -- Market Talk

5 nov 2025, 23:42 UTC

Marktinformatie

Gold Edges Lower Amid Reduced Odds of Fed Rate-Cut -- Market Talk

5 nov 2025, 23:12 UTC

Winsten

Nutrien 3Q Adj EPS 97c >NTR.T

5 nov 2025, 23:11 UTC

Winsten

Nutrien: Initiating Review of Strategic Alternatives for Phosphate Business >NTR.T

5 nov 2025, 23:10 UTC

Winsten

Nutrien 3Q Sales $6.01B >NTR.T

5 nov 2025, 23:10 UTC

Marktinformatie
Winsten

AppLovin Says Conversion Rate Is Biggest Growth Lever -- Market Talk

5 nov 2025, 23:10 UTC

Winsten

Nutrien 3Q EPS 96c >NTR.T

5 nov 2025, 23:04 UTC

Winsten

Qualcomm Stock Slides After Earnings Beat -- Barrons.com

5 nov 2025, 23:03 UTC

Marktinformatie

Macklem: Canada's Regulatory Overlap Turns Off Foreign Investors -- Market Talk

5 nov 2025, 22:55 UTC

Marktinformatie

Macklem Says Inflation and Productivity Are Intertwined -- Market Talk

5 nov 2025, 22:55 UTC

Winsten

AppLovin Reports Strong Earnings. The Stock Is Up. -- Barrons.com

5 nov 2025, 22:51 UTC

Winsten

DBS 3Q Total Income S$5.93B, Up 3% on Year >D05.SG

5 nov 2025, 22:50 UTC

Winsten

DBS 3Q Net S$2.95B, Down 2.0% on Year >D05.SG

5 nov 2025, 22:44 UTC

Acquisities, Fusies, Overnames

Pfizer Preps Improved Offer in Metsera Bidding War -- Update

5 nov 2025, 22:43 UTC

Marktinformatie
Winsten

NAB's Flat Dividend Disappoints Bears at Jarden -- Market Talk

5 nov 2025, 22:36 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

5 nov 2025, 22:36 UTC

Marktinformatie

Macklem Warns Structural Adjustment Means Slow Canadian Growth -- Market Talk

5 nov 2025, 22:20 UTC

Marktinformatie

Bank of Canada Says Budget Plan Identifies Economy's Biggest Weakness -- Market Talk

5 nov 2025, 22:12 UTC

Acquisities, Fusies, Overnames

Pfizer: Will Take Action to Preserve Rights Under Previously-Signed Agreement >PFE

5 nov 2025, 22:11 UTC

Acquisities, Fusies, Overnames

Pfizer: Confident in Merits of Claims, Belief Metsera Has Acted in Breach of Contractual Obligations >PFE

5 nov 2025, 22:11 UTC

Acquisities, Fusies, Overnames

Pfizer Responds to Delaware Chancery Court Ruling

5 nov 2025, 22:01 UTC

Winsten

Great-West Lifeco 3Q Net C$1.16B >GWO.T

5 nov 2025, 22:01 UTC

Winsten

Great-West Lifeco 3Q Adj EPS C$1.33 >GWO.T

Peer Vergelijking

Prijswijziging

VIRIDIAN THERAPEUTICS INC Prognose

Koersdoel

By TipRanks

68.87% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 38.08 USD  68.87%

Hoogste 61 USD

Laagste 13.96 USD

Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor VIRIDIAN THERAPEUTICS INC - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

14 ratings

13

Buy

1

Hold

0

Sell

Technische score

By Trading Central

12 / 13.14Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Strong Bearish Evidence

Sentiment

By Acuity

165 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

help-icon Live chat